European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
The European Commission has approved Pfizer's HYMPAVZI for the treatment of adults and adolescents 12 years and older with hemophilia A or B with inhibitors. The approval is based on Phase 3 data from the BASIS trial, which demonstrated a 93% reduction in the mean treated annualized bleeding rate compared to on-demand therapy. HYMPAVZI is the only once-weekly subcutaneous treatment approved in the EU for both hemophilia A and B patients with inhibitors, offering a significant improvement in treatment options.
Key figures
- Drug Name
- HYMPAVZI (marstacimab)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.